782 TransCon TLR7/8 agonist induces sustained local and systemic immune activation in patients with solid tumors

• David Bajor,
• Nashat Gabrail,
• Alain Algazi,
• Diwakar Davar,
• Douglas Laux,
• Morteza Aghmesheh,
• Joan Morris,
• Vinod Ganju,
• Vibeke Miller Breinholt,
• Mette Kriegbaum,
• Alexander I Spira,
• Christian Krapp,
• Telma Lança,
• Stina Singel,
• Thomas Tuxen Poulsen

Affiliations

David Bajor

5Case Western Reserve University, Cleveland, OH, USA

Nashat Gabrail

11Gabrail Cancer Center, Canton, OH, USA

Alain Algazi

4UCSF Medical Center at Mission Bay, San Francisco, CA, USA

Diwakar Davar

1UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Douglas Laux

7Division of Oncology, University of Iowa, Iowa City, IA, USA

Morteza Aghmesheh

3Southern Medical Day Care Centre, Wollongong, NSW, Australia

Joan Morris

9Ascendis Pharma, Inc., Newbury Park, CA, USA

Vinod Ganju

6Peninsula and Southeast Oncology, Frankston, VIC, Australia

Vibeke Miller Breinholt

2Ascendis Pharma, Inc, Copenhagen, Denmark

Mette Kriegbaum

2Ascendis Pharma, Inc, Copenhagen, Denmark

Alexander I Spira

1Virginia Cancer Specialists, Fairfax, VA, USA

Christian Krapp

2Ascendis Pharma, Inc, Copenhagen, Denmark

Telma Lança

2Ascendis Pharma, Inc, Copenhagen, Denmark

Stina Singel

10Ascendis Pharma, Palo Alto, CA, USA

Thomas Tuxen Poulsen

2Ascendis Pharma, Inc, Copenhagen, Denmark